FINANCIAL STATEMENTS ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007 127 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 4 TAXATION CONTINUED Losses Pension Inter and tax Property, and postcompany Deferred credits plant and Intangible retirement inventory Untaxed Accrued Share capital carried 1 equipment assets bene ts transfers reserves expenses schemes gains forward Other T otal $m $m $m $m $m $m $m $m $m $m $m Deferred tax assets at 1 January 2007 37 2 604 853 323 113 57 28 2,017 Deferred tax liabilities at 1 January 2007 830 491 881 99 55 2,356 Net deferred tax balance at 1 January 2007 793 489 604 853 881 323 113 99 57 27 339 At 1 January 2007 793 489 604 853 881 323 113 99 57 27 339 Income statement 86 157 99 71 225 190 45 12 96 58 205 Statement of recognised income and expense 8 8 3 Acquisition of subsidiary undertaking 3 2,973 58 74 369 29 2,498 Exchange 35 5 15 46 65 11 2 1 1 33 Net deferred tax balance at 31 December 2007 911 3,310 528 886 1,171 598 62 88 330 1 3,075 Deferred tax assets at 31 December 2007 66 59 531 907 611 62 330 71 2,637 Deferred tax liabilities at 31 December 2007 977 3,369 3 21 1,171 13 88 70 5,712 Net deferred tax balance at 31 December 2007 911 3,310 528 886 1,171 598 62 88 330 1 3,075 2007 2006 2005 Analysed in the balance sheet, after offset of balances within countries, as: $m $m $m Deferred tax assets 1,044 1,220 1,117 Deferred tax liabilities 4,119 1,559 1,112 Net deferred tax balance 3,075 339 5 1 Untaxed reserves relate to taxable pro ts where the tax liability is deferred to later periods.
3 The deferred tax liability of $2,498m relates to MedImmune, Inc. and other acquisitions made during the course of the year Note 24.
Unrecognised deferred tax assets Deferred tax assets of $106m have not been recognised in respect of deductible temporary differences 2006 $103m, 2005 $87m because it is not probable that future taxable profit will be available against which the Group can utilise the benefits therefrom.
5 EARNINGS PER $0.25 ORDINARY SHARE 2007 2006 2005 Profit for the financial year $m 5,595 6,043 4,706 Basic earnings per Ordinary Share $3.74 $3.86 $2.91 Diluted earnings per Ordinary Share $3.73 $3.85 $2.91 Weighted average number of Ordinary Shares in issue for basic earnings millions 1,495 1,564 1,617 Dilutive impact of share options outstanding millions 3 6 1 Diluted weighted average number of Ordinary Shares in issue millions 1,498 1,570 1,618 There are no options, warrants or rights outstanding in respect of unissued shares except for employee share option schemes.
The number of options outstanding and the weighted average exercise price of these options is shown in Note 26.
The earnings figures used in the calculations above are post-tax and are unchanged for diluted earnings per Ordinary Share.
